Skip to main content
SpringerLink
Log in
Book cover

Atlas of Uterine Pathology pp 79–121Cite as

Epithelial and Mixed Epithelial/Mesenchymal Malignancies of the Uterine Corpus

  • Chapter
  • First Online:

  • 1203 Accesses

Part of the book series: Atlas of Anatomic Pathology ((AAP))

Abstract

Cancers of the uterine corpus are the most frequently diagnosed malignancies of the female genital tract in the United States, with an estimated 61,880 new cases and 12,160 associated deaths expected for 2019. Endometrial carcinomas, which represent more than 95% of uterine corpus cancers, are heterogeneous as a group, and have been shown to be classifiable into clinically relevant subsets using morphological/immunophenotypic and molecular modalities. The recognized histotypes encapsulate the biologic profiles of the subclasses, albeit imperfectly, and accordingly continue to serve as a surrogate indicator for defining these clinically relevant subsets. This chapter illustrates the most salient pathologic features of epithelial and mixed epithelial/mesenchymal malignancies of the uterine corpus, with an emphasis on core appearances, morphologic variations, and immunophenotypic features.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:7–34.

    Article  Google Scholar 

  2. Soslow RA, Tornos C, Park KJ, Malpica A, Matias-Guiu X, Oliva E, et al. Endometrial carcinoma diagnosis: use of FIGO grading and genomic subcategories in clinical practice: recommendations of the international society of gynecological pathologists. Int J Gynecol Pathol. 2019;38(Suppl 1):S64–74.

    PubMed  Google Scholar 

  3. Murali R, Davidson B, Fadare O, Carlson JA, Crum CP, Gilks CB, et al. High-grade endometrial carcinomas: morphologic and immunohistochemical features, diagnostic challenges and recommendations. Int J Gynecol Pathol. 2019;38(Suppl 1):S40–63.

    PubMed  Google Scholar 

  4. Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, et al. Integrated genomic characterization of endometrial carcinoma. Nature. 2013;497:67–73.

    Google Scholar 

  5. Creasman WT, Odicino F, Maisonneuve P, Quinn MA, Beller U, Benedet JL, et al. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S105–43.

    PubMed  Google Scholar 

  6. Altman AD, Ferguson SE, Atenafu EG, Köbel M, McAlpine JN, Panzarella T, et al. Canadian high risk endometrial cancer (CHREC) consortium: analyzing the clinical behavior of high risk endometrial cancers. Gynecol Oncol. 2015;139:268–74.

    PubMed  Google Scholar 

  7. Zaino RJ, Kurman RJ, Diana KL, Morrow CP. The utility of the revised International Federation of Gynecology and Obstetrics histologic grading of endometrial adenocarcinoma using a defined nuclear grading system. A Gynecologic Oncology Group study. Cancer. 1995;75:81–6.

    CAS  PubMed  Google Scholar 

  8. Li Z, Zhao C. Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma. Appl Immunohistochem Mol Morphol. 2016;24:562–8.

    CAS  PubMed  Google Scholar 

  9. Zaino RJ, Kurman RJ. Squamous differentiation in carcinoma of the endometrium: a critical appraisal of adenoacanthoma and adenosquamous carcinoma. Semin Diagn Pathol. 1988;5:154–71.

    CAS  PubMed  Google Scholar 

  10. Nicolae A, Preda O, Nogales FF. Endometrial metaplasias and reactive changes: a spectrum of altered differentiation. J Clin Pathol. 2011;64:97–106.

    PubMed  Google Scholar 

  11. McCluggage WG, Van de Vijver K. SATB2 is consistently expressed in squamous morules associated with endometrioid proliferative lesions and in the stroma of atypical polypoid adenomyoma. Int J Gynecol Pathol. 2018; https://doi.org/10.1097/PGP.0000000000000544. [Epub ahead of print].

  12. Tobon H, Watkins GJ. Secretory adenocarcinoma of the endometrium. Int J Gynecol Pathol. 1985;4:328–35.

    CAS  PubMed  Google Scholar 

  13. Christopherson WM, Alberhasky RC, Connelly PJ. Carcinoma of the endometrium: I. a clinicopathologic study of clear-cell carcinoma and secretory carcinoma. Cancer. 1982;49:1511–23.

    CAS  PubMed  Google Scholar 

  14. Ambros RA, Ballouk F, Malfetano JH, Ross JS. Significance of papillary (villoglandular) differentiation in endometrioid carcinoma of the uterus. Am J Surg Pathol. 1994;18:569–75.

    CAS  PubMed  Google Scholar 

  15. Zaino RJ, Kurman RJ, Brunetto VL, Morrow CP, Bentley RC, Cappellari JO, Bitterman P. Villoglandular adenocarcinoma of the endometrium: a clinicopathologic study of 61 cases: a Gynecologic Oncology Group study. Am J Surg Pathol. 1998;22:1379–85.

    CAS  PubMed  Google Scholar 

  16. Malpica A. How to approach the many faces of endometrioid carcinoma. Mod Pathol. 2016;29(Suppl 1):S29–44.

    CAS  PubMed  Google Scholar 

  17. Zaino R, Carinelli SG, Ellenson LH, et al. Tumors of the uterine corpus. Epithelial tumours and precursors. In: Kurman RJ, Carcangiu ML, Herrington CS, Young RH, editors. World Health Organization classification of tumors of female reproductive organs. Lyon: IARC Press; 2014. p. 125–33.

    Google Scholar 

  18. Espinosa I, D’Angelo E, Corominas M, Gonzalez A, Prat J. Mixed endometrial carcinomas with a “low-grade serous”-like component: a clinicopathologic, immunohistochemical, and molecular genetic study. Hum Pathol. 2018;71:65–73.

    PubMed  Google Scholar 

  19. Murray SK, Young RH, Scully RE. Uterine endometrioid carcinoma with small nonvillous papillae: an analysis of 26 cases of a favorable-prognosis tumor to be distinguished from serous carcinoma. Int J Surg Pathol. 2000;8:279–89.

    PubMed  Google Scholar 

  20. Fadare O, Brooks AS, Martel M. A 54-year-old woman with menorrhagia. Mixed mucinous and endometrioid carcinoma with small nonvillous papillae. Arch Pathol Lab Med. 2006;130:400–2.

    PubMed  Google Scholar 

  21. Pitman MB, Young RH, Clement PB, Dickersin GR, Scully RE. Endometrioid carcinoma of the ovary an endometrium, oxyphilic cell type: a report of nine cases. Int J Gynecol Pathol. 1994;13:290–301.

    CAS  PubMed  Google Scholar 

  22. Silver SA, Cheung ANY, Tavassoli FA. Oncocytic metaplasia and carcinoma of the endometrium: an immunohistochemical and ultrastructural study. Int J Gynecol Pathol. 1999;18:12–9.

    CAS  PubMed  Google Scholar 

  23. Eichhorn JH, Young RH, Clement PB. Sertoliform endometrial adenocarcinoma: a study of four cases. Int J Gynecol Pathol. 1996;15:9–26.

    Google Scholar 

  24. Usadi RS, Bentley RC. Endometrioid carcinoma of the endometrium with sertoliform differentiation. Int J Gynecol Pathol. 1995;14:360–4.

    CAS  PubMed  Google Scholar 

  25. Murray SK, Clement PB, Young RH. Endometrioid carcinomas of the uterine corpus with sex cord-like formations, hyalinization, and other unusual morphologic features: a report of 31 cases of a neoplasm that may be confused with carcinosarcoma and other uterine neoplasms. Am J Surg Pathol. 2005;29:157–66.

    PubMed  Google Scholar 

  26. Tornos C, Silva EG, McCabe KM, et al. The spindle cell variant of endometrioid carcinoma [Abstract]. Mod Pathol. 1992;5:69A.

    Google Scholar 

  27. Young RH, Scully RE. Uterine carcinomas simulating microglandular hyperplasia: a report of six cases. Am J Surg Pathol. 1992;16:1092–7.

    CAS  PubMed  Google Scholar 

  28. Qiu W, Mittal K. Comparison of morphologic and immunohistochemical features of cervical microglandular hyperplasia with low-grade mucinous adenocarcinoma of the endometrium. Int J Gynecol Pathol. 2003;22:261–5.

    PubMed  Google Scholar 

  29. Cameron RI, Maxwell P, Jenkins D, McCluggage WG. Immunohistochemical staining with MIB1, bcl2 and p16 assists in the distinction of cervical glandular intraepithelial neoplasia from tubo-endometrial metaplasia, endometriosis and microglandular hyperplasia. Histopathology. 2002;41:313–21.

    CAS  Google Scholar 

  30. Chekmareva M, Ellenson LH, Pirog EC. Immunohistochemical differences between mucinous and microglandular adenocarcinomas of the endometrium and benign endocervical epithelium. Int J Gynecol Pathol. 2008;27:547–54.

    PubMed  Google Scholar 

  31. Pavlakis K, Vrekoussis T, Messini I, Voulgaris Z, Chrysanthakis D, Yiannou P, et al. Mucinous epithelial lesions in endometrial curettage material: a diagnostic challenge. Appl Immunohistochem Mol Morphol. 2012;20:607–13.

    CAS  PubMed  Google Scholar 

  32. Ross JC, Eifel PJ, Cox RS, Kempson RL, Hendrickson MR. Primary mucinous adenocarcinoma of the endometrium. A clinicopathologic and histochemical study. Am J Surg Pathol. 1983;7:715–29.

    CAS  PubMed  Google Scholar 

  33. Gungorduk K, Ozdemir A, Ertas IE, Selcuk I, Solmaz U, Ozgu E, et al. Is mucinous adenocarcinoma of the endometrium a risk factor for lymph node involvement? A multicenter case-control study. Int J Clin Oncol. 2015;20:782–9.

    CAS  PubMed  Google Scholar 

  34. Rauh-Hain JA, Vargas RJ, Clemmer J, Clark RM, Bradford LS, Growdon WB, et al. Mucinous adenocarcinoma of the endometrium compared with endometrioid endometrial cancer: a SEER analysis. Am J Clin Oncol. 2016;39:43–8.

    CAS  PubMed  Google Scholar 

  35. Musa F, Huang M, Adams B, Pirog E, Holcomb K. Mucinous histology is a risk factor for nodal metastases in endometrial cancer. Gynecol Oncol. 2012;125:541–5.

    PubMed  Google Scholar 

  36. Jackson CL, Hang S, Hansen K, He M, Sung CJ, Quddus MR, et al. Endometrial adenocarcinomas with significant mucinous differentiation: a characterization of intratumoral heterogeneity of KRAS mutations in mucinous and endometrioid histologic components. Int J Gynecol Cancer. 2018;28:241–7.

    PubMed  Google Scholar 

  37. Hamilton CA, Cheung MK, Osann K, Chen L, Teng NN, Longacre TA, et al. Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers. Br J Cancer. 2006;94:642–6.

    CAS  PubMed  PubMed Central  Google Scholar 

  38. Fadare O, Desouki MM, Roma AA, Parkash V, Zheng W. Endometrial serous carcinoma with pseudo-endometrioid features in biopsies and curettages: the diagnostic value of “focal apical anaplastic nuclei”. USCAP Annual Meeting, San Antonio, TX, March 2017.

    Google Scholar 

  39. Hariri N, Qarmali M, Fadare O. Endometrial serous carcinoma with clear-cell change: frequency and immunohistochemical analysis. Int J Surg Pathol. 2018;26:126–34.

    PubMed  Google Scholar 

  40. Fadare O, Roma AA, Parkash V, Zheng W, Walavalkar V. Does a p53 “wild-type” immunophenotype exclude a diagnosis of endometrial serous carcinoma? Adv Anat Pathol. 2018;25:61–70.

    PubMed  Google Scholar 

  41. Yemelyanova A, Ji H, Shih IM, Wang TL, Wu LS, Ronnett BM. Utility of p16 expression for distinction of uterine serous carcinomas from endometrial endometrioid and endocervical adenocarcinomas: immunohistochemical analysis of 201 cases. Am J Surg Pathol. 2009;33:1504–14.

    PubMed  Google Scholar 

  42. Köbel M, Atenafu EG, Rambau PF, Ferguson SE, Nelson GS, Ho TC, et al. Progesterone receptor expression is associated with longer overall survival within high-grade histotypes of endometrial carcinoma: a Canadian high risk endometrial cancer consortium (CHREC) study. Gynecol Oncol. 2016;141:559–63.

    PubMed  Google Scholar 

  43. Zheng W, Yi X, Fadare O, Liang SX, Martel M, Schwartz PE, Jiang Z. The oncofetal protein IMP3: a novel biomarker for endometrial serous carcinoma. Am J Surg Pathol. 2008;32:304–15.

    PubMed  Google Scholar 

  44. Fadare O, Zheng W. Insights into endometrial serous carcinogenesis and progression. Int J Clin Exp Pathol. 2009;2:411–32.

    CAS  PubMed  PubMed Central  Google Scholar 

  45. Rabban JT, Gilks CB, Malpica A, Matias-Guiu X, Mittal K, Mutter GL, et al. Issues in the differential diagnosis of uterine low-grade endometrioid carcinoma, including mixed endometrial carcinomas: recommendations from the international society of gynecological pathologists. Int J Gynecol Pathol. 2019;38(Suppl 1):S25–39.

    PubMed  Google Scholar 

  46. Rawish KR, Buza N, Zheng W, Fadare O. Endometrial carcinoma with trophoblastic components: clinicopathologic analysis of a rare entity. Int J Gynecol Pathol. 2018;37:174–90.

    CAS  PubMed  Google Scholar 

  47. Altrabulsi B, Malpica A, Deavers MT, Bodurka DC, Broaddus R, Silva EG. Undifferentiated carcinoma of the endometrium. Am J Surg Pathol. 2005;29:1316–21.

    PubMed  Google Scholar 

  48. Tafe LJ, Garg K, Chew I, Tornos C, Soslow RA. Endometrial and ovarian carcinomas with undifferentiated components: clinically aggressive and frequently underrecognized neoplasms. Mod Pathol. 2010;23:781–9.

    CAS  PubMed  Google Scholar 

  49. Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF, et al. Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer. 2006;106:87–94.

    CAS  PubMed  Google Scholar 

  50. Hoang LN, Lee YS, Karnezis AN, Tessier-Cloutier B, Almandani N, Coatham M, et al. Immunophenotypic features of dedifferentiated endometrial carcinoma – insights from BRG1/INI1-deficient tumours. Histopathology. 2016;69:560–9.

    PubMed  PubMed Central  Google Scholar 

  51. Köbel M, Hoang LN, Tessier-Cloutier B, Meng B, Soslow RA, Stewart CJR, Lee CH. Undifferentiated endometrial carcinomas show frequent loss of core switch/sucrose nonfermentable complex proteins. Am J Surg Pathol. 2018;42:76–83.

    PubMed  Google Scholar 

  52. Tessier-Cloutier B, Soslow RA, Stewart CJR, Köbel M, Lee CH. Frequent loss of claudin-4 expression in dedifferentiated and undifferentiated endometrial carcinomas. Histopathology. 2018;73:299–305.

    PubMed  PubMed Central  Google Scholar 

  53. Fadare O, Zheng W, Crispens MA, Jones HW, Khabele D, Gwin K, et al. Morphologic and other clinicopathologic features of endometrial clear cell carcinoma: a comprehensive analysis of 50 rigorously classified cases. Am J Cancer Res. 2013;3:70–95.

    PubMed  PubMed Central  Google Scholar 

  54. Fadare O, Renshaw IL, Liang SX. Expression of tissue factor and heparanase in endometrial clear cell carcinoma: possible role for tissue factor in thromboembolic events. Int J Gynecol Pathol. 2011;30:252–61.

    PubMed  Google Scholar 

  55. Fadare O, Desouki MM, Gwin K, Hanley KZ, Jarboe EA, Liang SX, et al. Frequent expression of napsin A in clear cell carcinoma of the endometrium: potential diagnostic utility. Am J Surg Pathol. 2014;38:189–96.

    PubMed  Google Scholar 

  56. Fadare O, Liang SX. Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas: lack of specificity for endometrial clear cell carcinoma. Appl Immunohistochem Mol Morphol. 2012;20:580–7.

    CAS  PubMed  Google Scholar 

  57. Bures N, Nelson G, Duan Q, Magliocco A, Demetrick D, Duggan MA. Primary squamous cell carcinoma of the endometrium: clinicopathologic and molecular characteristics. Int J Gynecol Pathol. 2013;32:566–75.

    CAS  PubMed  Google Scholar 

  58. Jones MA, Young RH, Scully RE. Endometrial adenocarcinoma with a component of giant cell carcinoma. Int J Gynecol Pathol. 1991;10:260–70.

    CAS  PubMed  Google Scholar 

  59. Mulligan AM, Plotkin A, Rouzbahman M, Soslow RA, Gilks CB, Clarke BA. Endometrial giant cell carcinoma: a case series and review of the spectrum of endometrial neoplasms containing giant cells. Am J Surg Pathol. 2010;34:1132–8.

    PubMed  Google Scholar 

  60. Pocrnich CE, Ramalingam P, Euscher ED, Malpica A. Neuroendocrine carcinoma of the endometrium: a clinicopathologic study of 25 cases. Am J Surg Pathol. 2016;40:577–86.

    PubMed  PubMed Central  Google Scholar 

  61. McFarland M, Quick CM, McCluggage WG. Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas. Histopathology. 2016;68:1013–20.

    PubMed  Google Scholar 

  62. Kolin DL, Costigan DC, Dong F, Nucci MR, Howitt BE. A combined morphologic and molecular approach to retrospectively identify KRAS-mutated mesonephric-like adenocarcinomas of the endometrium. Am J Surg Pathol. 2019;43:389–98.

    PubMed  Google Scholar 

  63. Mirkovic J, McFarland M, Garcia E, Sholl LM, Lindeman N, MacConaill L, et al. Targeted genomic profiling reveals recurrent KRAS mutations in mesonephric-like adenocarcinomas of the female genital tract. Am J Surg Pathol. 2018;42:227–33.

    PubMed  Google Scholar 

  64. Patel V, Kipp B, Schoolmeester JK. Corded and hyalinized mesonephric-like adenocarcinoma of the uterine corpus: report of a case mimicking endometrioid carcinoma. Hum Pathol. 2018; https://doi.org/10.1016/j.humpath.2018.08.018. [Epub ahead of print].

  65. Pors J, Cheng A, Leo JM, Kinloch MA, Gilks B, Hoang L. A comparison of GATA3, TTF1, CD10, and calretinin in identifying mesonephric and mesonephric-like carcinomas of the gynecologic tract. Am J Surg Pathol. 2018;42:1596–606.

    PubMed  Google Scholar 

  66. Ferguson SE, Tornos C, Hummer A, Barakat RR, Soslow RA. Prognostic features of surgical stage I uterine carcinosarcoma. Am J Surg Pathol. 2007;31:1653–61.

    PubMed  Google Scholar 

  67. Cherniack AD, Shen H, Walter V, Stewart C, Murray BA, Bowlby R, Cancer Genome Atlas Research Network, et al. Integrated molecular characterization of uterine carcinosarcoma. Cancer Cell. 2017;31:411–23.

    CAS  PubMed  PubMed Central  Google Scholar 

  68. McCluggage WG. Müllerian adenosarcoma of the female genital tract. Adv Anat Pathol. 2010;17:122–9.

    PubMed  Google Scholar 

  69. Fadare O, Parkash V, Desouki MM. Müllerian adenosarcoma of the uterus and its diagnostic mimics. AJSP: Rev Reports. 2016;21:82–92.

    Google Scholar 

  70. Kumar NB, Hart WR. Metastases to the uterine corpus from extragenital cancers. A clinicopathologic study of 63 cases. Cancer. 1982;50:2163–9.

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University of California, San Diego, La Jolla, CA, USA

    Oluwole Fadare & Andres A. Roma

Authors
  1. Oluwole Fadare
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Andres A. Roma
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Fadare, O., Roma, A.A. (2019). Epithelial and Mixed Epithelial/Mesenchymal Malignancies of the Uterine Corpus. In: Atlas of Uterine Pathology. Atlas of Anatomic Pathology. Springer, Cham. https://doi.org/10.1007/978-3-030-17931-1_4

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-17931-1_4

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-17930-4

  • Online ISBN: 978-3-030-17931-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation